U.S. markets closed

Aspira Women's Health Inc. (AWH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.7800-0.1700 (-3.43%)
At close: 4:00PM EDT

4.7800 0.00 (0.00%)
After hours: 4:00PM EDT

Sign in to post a message.
  • P
    Patrick
    This stock has all the makings of a 10 bagger. OVA/OVA1 in my opinion will never materialize and that is why the stock was trading under $1 until this time last year. When the news started coming out that ENDO was for real, the stock started climbing. This stocks entire rise(hopefully) will be do to ENDO. Lets just hope they can push it past the FDA this year. Genius that they decided to partner with ABBV this go round. Can't imagine they do not get it through the FDA just a question of timing in my opinion. All I hope is it gets through before they have to raise again.
  • M
    Mark
    Here is an enlightening exercise: Go to Yahoo Finance AWH, Summary. Click on chart of stock price, "Max". What do you see?
  • K
    KING REYOB
    Cover up shorts! With OVA ready to go for 2022 at roughly $800 per test we will start to see real revenue. Not to mention the huge market for ENDO. With these two products nearly to market the sky is the limit. Do you research fellas, your not gonna want to miss the next few years. It is going to be a wild ride!
    Bullish
  • s
    scott
    At $9.00 it was time to call it a day and be out of this one ...unfortunately I didn’t and in for long haul. I guess I should be happy ...at one point it was down to .70 Been in this for many many years !!!!! The day it hit $10 was the golden opportunity back in January. Could be a very long time before we see that again
  • s
    stocktargetadvisor
    $AWH
    Initiated by Truist Securities Buy USD 12
  • J
    Jimmy
    after hours $$$
  • O
    Oscar
    well guys, 12$+
  • g
    grant
    Just read earnings. I am excited. Who else is grabbing shares early tomorrow morning?
  • M
    Mark
    Did you all see the March 26 8-K? Revenues for 2020 were about $4.5 million, up from $4.4 in 2019. A market cap of $734 million indicates that the company is worth 163 times revenues, for a company with minimal growth. The only thing that is growing are the losses, $17 million, up from $15 million. This stock is realistically worth maybe 25 cents.
  • P
    Patrick
    What is going on with this stock after hours? Anyone have any insight?
    Bullish
  • c
    centofanti
    Winners don’t come often when you are out there in the wild world of the markets. But all that can change if you join the right program. I joined up with these guys (http://Stocks-tracker.com). Now I am having solid picks every week.
  • s
    scott
    Is anyone waiting for CC to start???
  • P
    Patrick
    Can anyone post any research reports on AWH? I would like to learn and read up as much as I can on the company. Are there any reports from analysist covering the stock?
    Bullish
  • M
    Mark
    23 year in business, and they have one approved diagnostic test that is selling approximately $4 million per year. Management is key. Track record is key. This is an horrific track record. Don't believe what people say; look at what they do. They raise money, and burn through it, paying themselves handsomely for terrible performance.
  • K
    KING REYOB
    Looks like my $1400 will be buying more AWH on the dip.
  • M
    Mark
    Theranos.
  • J
    Jon
    Not sure why anyone would sell here. Sales team up to 20 people. Just started to gain traction. Best days are ahead. Will become the standard of testing as its clearly superior. Even if the current management team can't get it done, the test and patents are worth far more than the 34M market cap.
  • J
    Jeff
    "next move on share price" ..thats what we are all asking. My advice is don't listen to anyone but your gut/gestalt and watch the tape. The market dictates what will happen. The market is telling us so far its heading north at least for now. It appears FINALLY ob/gyn/oncologists are adapting ova1/overa as "standard of care " diagnostic for ovarian cancer. BETTER test than CEA125. Last 3 quarters exponential >50% growth . I think the million dollar question is how well AWH has pivoted to virtual sales. I hope this next quarter reveals continuation of the recent exponential growth. Fingers crossed. I am very long and wish you well in your investment.
  • S
    Saville12
    Nice movement today, here's to it continuing!
  • M
    Mark
    I just reviewed the most recent financial statement of Aspira, and the results are not good, to say the least. Here are some highlights:
    1. The company has spent approximately $400 million to end up in the position it is today. (Accumulated deficit of $433,985,000).
    2. The position they are in today, after approximately 23 year in business, is that they have one approved diagnostic test that is selling approximately $4 million per year.
    3. This product is a commercial failure by any measure. The company is spending approximately $8 million per year on Sales and Marketing expense, and all they got for that was $4 million in annual sales.
    4. So, based on the valuation of $900 million, they must have some incredible products coming along, right? Ok, but for the past two years, they have spent only about $1 million per year on Research and Development. How do you create products worth $900 million (the company value) with that kind of money spent? Well, maybe if you are geniuses. Do we have geniuses here, geniuses that after 23 years in business they end up with a product that sells $4 million per year, with marketing expenses of $8 million? I don’t think so.
    5. So, what do we have here? What kind of people are running this company? Where did all the money go? Well, in 2019, General and Administrative expenses were about $5.8 million. That would be salaries and overhead of the people running the company. That is more than 5 times the amount spent on R&D. That goes to salaries of the management of like $940,000 for top person, and on down. Plus equity incentives and God knows what other kind of perks.
    In my opinion, this company is not what many people have been led to believe, its not a company that cares much about women (or they would spend more on R & D); it is a company that is highly overvalued as a result of an emotional appeal of helping women, and run by people taking advantage of investors. It really is a travesty, which is why I took the time to write this, and why I just shorted the stock.